Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety (Q38126945)

29 August 2017

title

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety (English)

1 reference

29 August 2017

1 reference

Carolyn F Deacon

0 references

Jens J Holst

0 references

language of work or name

English

0 references

publication date

7 August 2013

1 reference

Expert Opinion on Pharmacotherapy

29 August 2017

published in

1 reference

29 August 2017

1 reference

29 August 2017

1 reference

29 August 2017

page(s)

2047-2058

1 reference

The Physiology of Glucagon-like Peptide 1

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Glucagon-like peptide-1, glucose homeostasis and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

The safety of incretin-based therapies--review of the scientific evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Incretin therapy and islet pathology: a time for caution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Tolerability of dipeptidyl peptidase-4 inhibitors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Sitagliptin reduces albuminuria in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Potential cardiovascular effects of incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.824966

10.1517/14656566.2013.824966

21 January 2018

Identifiers

DOI

1 reference

release_rhcia5po3jatldqajkippzline

29 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rhcia5po3jatldqajkippzline

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference